Related Experiment Video
Updated: Jun 16, 2026
05:44
Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
Published on: October 13, 2023
MGAT5 alters the severity of multiple sclerosis
B Brynedal1, J Wojcik, F Esposito
1The MS research group, Center for Molecular Medicine CMM L8:00, Department of Clinical Neuroscience, Karolinska Institutet, 171 76 Stockholm, Sweden. boel.brynedal@ki.se
Journal of Neuroimmunology
|February 2, 2010
Summary
Genetic factors influencing Multiple Sclerosis (MS) severity were investigated. Researchers identified specific markers in the MGAT5 gene associated with disease outcome in MS patients.
Area of Science:
- Neuroimmunology
- Genetics
- Biochemistry
Background:
- Multiple Sclerosis (MS) is a complex immune-mediated demyelinating disease of the central nervous system.
- Genetic factors contributing to MS severity remain largely unknown.
- Previous studies have not definitively linked genetic variants to MS disease progression.
Purpose of the Study:
- To identify genetic variants associated with disease severity in Multiple Sclerosis.
- To conduct a genome-wide association study for MS severity.
Main Methods:
- Genome-wide screening utilizing Affymetrix Genechip 500K technology.
- Analysis of 1040 Multiple Sclerosis patients.
- Replication in an independent patient cohort.
Main Results:
- Two genetic markers within the MGAT5 gene showed significant association with MS outcome.
- Combined p-values for the association were 2.8 x 10(-6) and 1.5 x 10(-7).
- MGAT5 encodes a glycosylation enzyme.
Conclusions:
- The MGAT5 gene is a potential genetic contributor to Multiple Sclerosis severity.
- These findings warrant further investigation into the role of MGAT5 in MS pathogenesis.
- Genetic insights into MS severity could inform future therapeutic strategies.
More Related Videos
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...